{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:11:51Z","timestamp":1792156311551,"version":"4.4.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82501547"],"award-info":[{"award-number":["82501547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023TQ0284"],"award-info":[{"award-number":["2023TQ0284"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07971-z","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:06:36Z","timestamp":1773108396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects"],"prefix":"10.1186","volume":"24","author":[{"given":"Tianyun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangzhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kankai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"Suppl 5","key":"7971_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, et al. Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019. Neuro Oncol. 2022;24(Suppl 5):v1\u201395.","journal-title":"Neuro Oncol"},{"issue":"10","key":"7971_CR2","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","volume":"23","author":"JP Thakkar","year":"2014","unstructured":"Thakkar JP, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985\u201396.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7971_CR3","doi-asserted-by":"crossref","unstructured":"Ostrom QT, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010. Neuro Oncol. 2013;15 Suppl 2(Suppl 2): p. ii1\u201356.","DOI":"10.1093\/neuonc\/not151"},{"issue":"10","key":"7971_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"key":"7971_CR5","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.nantod.2022.101435","volume":"43","author":"Y Pan","year":"2022","unstructured":"Pan Y, et al. Localized NIR-II laser mediated chemodynamic therapy of glioblastoma. Nano Today. 2022;43:101435.","journal-title":"Nano Today"},{"issue":"4","key":"7971_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jnci.2016.07.001","volume":"28","author":"S Mallick","year":"2016","unstructured":"Mallick S, et al. Management of glioblastoma after recurrence: A changing paradigm. J Egypt Natl Canc Inst. 2016;28(4):199\u2013210.","journal-title":"J Egypt Natl Canc Inst"},{"key":"7971_CR7","doi-asserted-by":"crossref","unstructured":"Seker-Polat F, et al. Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives. Cancers (Basel). 2022;14(2).","DOI":"10.3390\/cancers14020443"},{"issue":"5","key":"7971_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/jnnp.2003.025031","volume":"75","author":"TJ Hulsebos","year":"2004","unstructured":"Hulsebos TJ, Troost D, Leenstra S. Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours. J Neurol Neurosurg Psychiatry. 2004;75(5):723\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7971_CR9","doi-asserted-by":"crossref","unstructured":"Ou A, Yung WKA, Majd N. Molecular mechanisms of treatment resistance in glioblastoma. Int J Mol Sci. 2020;22(1).","DOI":"10.3390\/ijms22010351"},{"issue":"48","key":"7971_CR10","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1039\/C9TB01651A","volume":"7","author":"YB Pan","year":"2019","unstructured":"Pan YB, et al. A combination of glioma in vivo imaging and in vivo drug delivery by metal-organic framework based composite nanoparticles. J Mater Chem B. 2019;7(48):7683\u20139.","journal-title":"J Mater Chem B"},{"issue":"11","key":"7971_CR11","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3174\/ajnr.A2397","volume":"32","author":"LC Hygino da Cruz Jr","year":"2011","unstructured":"Hygino da Cruz LC Jr., et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978\u201385.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"7971_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0317167100009628","volume":"37","author":"P Sanghera","year":"2010","unstructured":"Sanghera P, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci. 2010;37(1):36\u201342.","journal-title":"Can J Neurol Sci"},{"key":"7971_CR13","doi-asserted-by":"publisher","first-page":"1611875","DOI":"10.3389\/pore.2024.1611875","volume":"30","author":"T Aghova","year":"2024","unstructured":"Aghova T, et al. Diagnostic challenges in complicated case of glioblastoma. Pathol Oncol Res. 2024;30:1611875.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"7971_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2214\/AJR.11.7417","volume":"198","author":"GM Fatterpekar","year":"2012","unstructured":"Fatterpekar GM, et al. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum\u2013use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol. 2012;198(1):19\u201326.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"7971_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453\u201361.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7971_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-009-9809-4","volume":"94","author":"ER Gerstner","year":"2009","unstructured":"Gerstner ER, et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009;94(1):97\u2013101.","journal-title":"J Neurooncol"},{"issue":"3","key":"7971_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00401-005-0023-y","volume":"111","author":"A Perry","year":"2006","unstructured":"Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol. 2006;111(3):197\u2013212.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"7971_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/toxins3030191","volume":"3","author":"AI Mehta","year":"2011","unstructured":"Mehta AI, et al. Monitoring radiographic brain tumor progression. Toxins (Basel). 2011;3(3):191\u2013200.","journal-title":"Toxins (Basel)"},{"issue":"4","key":"7971_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441\u20136.","journal-title":"Eur J Cancer"},{"key":"7971_CR20","doi-asserted-by":"publisher","first-page":"46349","DOI":"10.1038\/srep46349","volume":"7","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, et al. Radiomics-based Prognosis Analysis for Non-Small Cell Lung Cancer. Sci Rep. 2017;7:46349.","journal-title":"Sci Rep"},{"key":"7971_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.semcancer.2020.04.002","volume":"72","author":"A Conti","year":"2021","unstructured":"Conti A, et al. Radiomics in breast cancer classification and prediction. Semin Cancer Biol. 2021;72:238\u201350.","journal-title":"Semin Cancer Biol"},{"key":"7971_CR22","doi-asserted-by":"crossref","unstructured":"Caruso D, et al. Radiomic cancer hallmarks to identify high-risk patients in non-metastatic colon cancer. Cancers (Basel). 2022; 14(14).","DOI":"10.3390\/cancers14143438"},{"key":"7971_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3389\/fonc.2019.00374","volume":"9","author":"A Chaddad","year":"2019","unstructured":"Chaddad A, et al. Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation. Front Oncol. 2019;9:374.","journal-title":"Front Oncol"},{"issue":"1","key":"7971_CR24","doi-asserted-by":"publisher","first-page":"10353","DOI":"10.1038\/s41598-017-10649-8","volume":"7","author":"J Lao","year":"2017","unstructured":"Lao J, et al. A Deep Learning-Based Radiomics Model for Prediction of Survival in Glioblastoma Multiforme. Sci Rep. 2017;7(1):10353.","journal-title":"Sci Rep"},{"key":"7971_CR25","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1016\/j.wneu.2019.01.157","volume":"125","author":"MH Lee","year":"2019","unstructured":"Lee MH, et al. Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data. World Neurosurg. 2019;125:e688\u201396.","journal-title":"World Neurosurg"},{"issue":"1","key":"7971_CR26","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/s41598-024-66653-2","volume":"14","author":"L Li","year":"2024","unstructured":"Li L, et al. Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis. Sci Rep. 2024;14(1):16031.","journal-title":"Sci Rep"},{"issue":"1","key":"7971_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12967-025-06101-5","volume":"23","author":"AB Ahanger","year":"2025","unstructured":"Ahanger AB, et al. Radiogenomics and machine learning predict oncogenic signaling pathways in glioblastoma. J Transl Med. 2025;23(1):121.","journal-title":"J Transl Med"},{"issue":"5","key":"7971_CR28","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s40120-023-00524-2","volume":"12","author":"J Ren","year":"2023","unstructured":"Ren J, et al. Multimodality MRI Radiomics Based on Machine Learning for Identifying True Tumor Recurrence and Treatment-Related Effects in Patients with Postoperative Glioma. Neurol Ther. 2023;12(5):1729\u201343.","journal-title":"Neurol Ther"},{"issue":"8","key":"7971_CR29","first-page":"3449","volume":"13","author":"P Du","year":"2023","unstructured":"Du P, et al. The application of decision tree model based on clinicopathological risk factors and pre-operative MRI radiomics for predicting short-term recurrence of glioblastoma after total resection: a retrospective cohort study. Am J Cancer Res. 2023;13(8):3449\u201362.","journal-title":"Am J Cancer Res"},{"key":"7971_CR30","doi-asserted-by":"publisher","first-page":"641878","DOI":"10.3389\/fonc.2021.641878","volume":"11","author":"W Chen","year":"2021","unstructured":"Chen W, et al. Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis. Front Oncol. 2021;11:641878.","journal-title":"Front Oncol"},{"key":"7971_CR31","doi-asserted-by":"publisher","first-page":"740413","DOI":"10.3389\/fonc.2021.740413","volume":"11","author":"T Wang","year":"2021","unstructured":"Wang T, et al. A Novel Nomogram for Predicting the Risk of Short-Term Recurrence After Surgery in Glioma Patients. Front Oncol. 2021;11:740413.","journal-title":"Front Oncol"},{"issue":"3","key":"7971_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","volume":"97","author":"G Minniti","year":"2010","unstructured":"Minniti G, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol. 2010;97(3):377\u201381.","journal-title":"Radiother Oncol"},{"issue":"1","key":"7971_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98\u2013110.","journal-title":"Cancer Cell"},{"issue":"04","key":"7971_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/nep3.69","volume":"2","author":"P Walczak","year":"2024","unstructured":"Walczak P, et al. Neurodegeneration in acute and chronic central nervous system disorders: Novel ideas and approaches. Neuroprotection. 2024;2(04):243\u20135.","journal-title":"Neuroprotection"},{"issue":"5","key":"7971_CR35","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.21037\/apm-21-823","volume":"10","author":"R Huang","year":"2021","unstructured":"Huang R, et al. A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma. Ann Palliat Med. 2021;10(5):5391\u20139.","journal-title":"Ann Palliat Med"},{"key":"7971_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/B978-0-12-802997-8.00023-2","volume":"134","author":"HG Wirsching","year":"2016","unstructured":"Wirsching HG, Galanis E, Weller M. Glioblastoma Handb Clin Neurol. 2016;134:381\u201397.","journal-title":"Glioblastoma Handb Clin Neurol"},{"issue":"4","key":"7971_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s10014-012-0084-2","volume":"29","author":"Y Okita","year":"2012","unstructured":"Okita Y, et al. Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 2012;29(4):192\u2013200.","journal-title":"Brain Tumor Pathol"},{"issue":"3","key":"7971_CR38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2174\/1574892818666230519150401","volume":"19","author":"M Xiong","year":"2024","unstructured":"Xiong M, et al. PSMA PET\/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis. Recent Pat Anticancer Drug Discov. 2024;19(3):383\u201395.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"3","key":"7971_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/00001622-200105000-00003","volume":"13","author":"JM Hoffman","year":"2001","unstructured":"Hoffman JM. New advances in brain tumor imaging. Curr Opin Oncol. 2001;13(3):148\u201353.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"7971_CR40","first-page":"201","volume":"25","author":"PA Hein","year":"2004","unstructured":"Hein PA, et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol. 2004;25(2):201\u20139.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"7971_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/annonc\/mdy506","volume":"30","author":"I Spiteri","year":"2019","unstructured":"Spiteri I, et al. Evolutionary dynamics of residual disease in human glioblastoma. Ann Oncol. 2019;30(3):456\u201363.","journal-title":"Ann Oncol"},{"issue":"1","key":"7971_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13014-022-02141-z","volume":"17","author":"K Yang","year":"2022","unstructured":"Yang K, et al. Comparative analysis of the prognosis of external beam radiation therapy (EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a SEER population-based study. Radiat Oncol. 2022;17(1):174.","journal-title":"Radiat Oncol"},{"issue":"11","key":"7971_CR43","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963\u201372.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7971_CR44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00066-017-1161-6","volume":"193","author":"C Straube","year":"2017","unstructured":"Straube C, et al. Re-irradiation after gross total resection of recurrent glioblastoma: Spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol. 2017;193(11):897\u2013909.","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"7971_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-008-9718-y","volume":"91","author":"RM Zuniga","year":"2009","unstructured":"Zuniga RM, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329\u201336.","journal-title":"J Neurooncol"},{"issue":"3","key":"7971_CR46","doi-asserted-by":"publisher","first-page":"e4647","DOI":"10.1002\/nbm.4647","volume":"35","author":"T Chougule","year":"2022","unstructured":"Chougule T, et al. Radiomics signature for temporal evolution and recurrence patterns of glioblastoma using multimodal magnetic resonance imaging. NMR Biomed. 2022;35(3):e4647.","journal-title":"NMR Biomed"},{"issue":"5","key":"7971_CR47","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/WNL.0b013e31820a0a8a","volume":"76","author":"WB Pope","year":"2011","unstructured":"Pope WB, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011;76(5):432\u20137.","journal-title":"Neurology"},{"issue":"1","key":"7971_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0029-1241190","volume":"71","author":"M Hefti","year":"2010","unstructured":"Hefti M, et al. Multicentric tumor manifestations of high grade gliomas: independent proliferation or hallmark of extensive disease? Cent Eur Neurosurg. 2010;71(1):20\u20135.","journal-title":"Cent Eur Neurosurg"},{"issue":"17","key":"7971_CR49","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/cancers15174279","volume":"15","author":"MA Vaz-Salgado","year":"2023","unstructured":"Vaz-Salgado MA, et al. Recurrent glioblastoma: a review of the treatment options. Cancers. 2023;15(17):4279.","journal-title":"Cancers"},{"key":"7971_CR50","doi-asserted-by":"crossref","unstructured":"Wang K, et al. HRH1-targeting mAb: a precision therapeutic strategy for glioblastoma. Oncogene. 2025:pp. 1\u201314.","DOI":"10.1038\/s41388-025-03613-8"},{"issue":"Supplement1","key":"7971_CR51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1227\/neu.0000000000002810_104","volume":"70","author":"MM Askun","year":"2024","unstructured":"Askun MM, et al. Repeat Resection for Recurrent Glioblastoma in the WHO 2021 Era: A Prospective Matched Case-Control Study. Neurosurgery. 2024;70(Supplement1):200.","journal-title":"Neurosurgery"},{"issue":"1","key":"7971_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","volume":"142","author":"F Kazmi","year":"2019","unstructured":"Kazmi F, et al. Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol. 2019;142(1):79\u201390.","journal-title":"J Neurooncol"},{"issue":"1","key":"7971_CR53","doi-asserted-by":"publisher","first-page":"e0317937","DOI":"10.1371\/journal.pone.0317937","volume":"20","author":"H Darwish","year":"2025","unstructured":"Darwish H, et al. Impact of re-operation on progression-free survival in patients with recurrent GBM: Experience in a tertiary referral center. PLoS ONE. 2025;20(1):e0317937.","journal-title":"PLoS ONE"},{"issue":"1","key":"7971_CR54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11060-025-05042-9","volume":"174","author":"S Mansoorian","year":"2025","unstructured":"Mansoorian S, et al. Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume. J Neurooncol. 2025;174(1):243\u201352.","journal-title":"J Neurooncol"},{"key":"7971_CR55","doi-asserted-by":"crossref","unstructured":"Lombardi G, et al. A new landscape for systemic pharmacotherapy of recurrent glioblastoma?. 2020;MDPI:p. 3775.","DOI":"10.3390\/cancers12123775"},{"issue":"1","key":"7971_CR56","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","volume":"23","author":"M Fu","year":"2023","unstructured":"Fu M, et al. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer. 2023;23(1):544.","journal-title":"BMC Cancer"},{"key":"7971_CR57","doi-asserted-by":"publisher","first-page":"103184","DOI":"10.1016\/j.critrevonc.2020.103184","volume":"157","author":"S Scoccianti","year":"2021","unstructured":"Scoccianti S, et al. Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery. Crit Rev Oncol\/Hematol. 2021;157:103184.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"7971_CR58","doi-asserted-by":"publisher","first-page":"e1553","DOI":"10.6061\/clinics\/2020\/e1553","volume":"75","author":"AC Faustino","year":"2020","unstructured":"Faustino AC, Viani GA, Hamamura AC. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. Clinics. 2020;75:e1553.","journal-title":"Clinics"},{"key":"7971_CR59","doi-asserted-by":"publisher","first-page":"1327621","DOI":"10.3389\/fncel.2023.1327621","volume":"17","author":"M Chiariello","year":"2023","unstructured":"Chiariello M, et al. Overcoming challenges in glioblastoma treatment: targeting infiltrating cancer cells and harnessing the tumor microenvironment. Front Cell Neurosci. 2023;17:1327621.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"7971_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/nop\/npad063","volume":"11","author":"H Blakstad","year":"2024","unstructured":"Blakstad H, et al. Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: a cohort study. Neuro-Oncology Pract. 2024;11(1):36\u201345.","journal-title":"Neuro-Oncology Pract"},{"key":"7971_CR61","doi-asserted-by":"crossref","unstructured":"Zikou A, et al. Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Volume 2018. Contrast Media Mol Imaging. 2018;2018(1):p. 6828396.","DOI":"10.1155\/2018\/6828396"},{"issue":"1","key":"7971_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40644-024-00682-y","volume":"24","author":"H Fan","year":"2024","unstructured":"Fan H, et al. Artificial intelligence-based MRI radiomics and radiogenomics in glioma. Cancer Imaging. 2024;24(1):36.","journal-title":"Cancer Imaging"},{"issue":"22","key":"7971_CR63","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1212\/WNL.0b013e31821d74e7","volume":"76","author":"R Young","year":"2011","unstructured":"Young R, et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology. 2011;76(22):1918\u201324.","journal-title":"Neurology"},{"issue":"12","key":"7971_CR64","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00234-024-03450-8","volume":"66","author":"R van den Elshout","year":"2024","unstructured":"van den Elshout R, et al. Distinguishing glioblastoma progression from treatment-related changes using DTI directionality growth analysis. Neuroradiology. 2024;66(12):2143\u201351.","journal-title":"Neuroradiology"},{"issue":"1","key":"7971_CR65","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12880-025-01929-1","volume":"25","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, et al. Heterogeneity phenotypes in recurrent glioblastoma: a multimodal MRI-based spatial mapping framework for precision treatment. BMC Med Imaging. 2025;25(1):386.","journal-title":"BMC Med Imaging"},{"issue":"1","key":"7971_CR66","doi-asserted-by":"publisher","first-page":"9974","DOI":"10.1038\/s41598-021-89218-z","volume":"11","author":"KY Shim","year":"2021","unstructured":"Shim KY, et al. Radiomics-based neural network predicts recurrence patterns in glioblastoma using dynamic susceptibility contrast-enhanced MRI. Sci Rep. 2021;11(1):9974.","journal-title":"Sci Rep"},{"issue":"12","key":"7971_CR67","first-page":"1688","volume":"19","author":"P Grossmann","year":"2017","unstructured":"Grossmann P, et al. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neurooncology. 2017;19(12):1688\u201397.","journal-title":"Neurooncology"},{"issue":"1","key":"7971_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/nep3.70003","volume":"3","author":"P Walczak","year":"2025","unstructured":"Walczak P, et al. Protecting the brain from multifaceted damage and promoting recovery. Neuroprotection. 2025;3(1):1\u20134.","journal-title":"Neuroprotection"},{"key":"7971_CR69","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","volume":"5","author":"HJ Aerts","year":"2014","unstructured":"Aerts HJ, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.","journal-title":"Nat Commun"},{"issue":"3","key":"7971_CR70","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/0008-5472.CAN-20-0999","volume":"81","author":"G Rossi","year":"2021","unstructured":"Rossi G, et al. Radiomic Detection of EGFR Mutations in NSCLC. Cancer Res. 2021;81(3):724\u201331.","journal-title":"Cancer Res"},{"issue":"1","key":"7971_CR71","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1038\/s41467-020-19116-x","volume":"11","author":"W Mu","year":"2020","unstructured":"Mu W, et al. Non-invasive decision support for NSCLC treatment using PET\/CT radiomics. Nat Commun. 2020;11(1):5228.","journal-title":"Nat Commun"},{"issue":"1","key":"7971_CR72","doi-asserted-by":"publisher","first-page":"19062","DOI":"10.1038\/s41598-023-46391-7","volume":"13","author":"M Selvam","year":"2023","unstructured":"Selvam M, et al. Radiomics as a non-invasive adjunct to Chest CT in distinguishing benign and malignant lung nodules. Sci Rep. 2023;13(1):19062.","journal-title":"Sci Rep"},{"issue":"3","key":"7971_CR73","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.21037\/jtd-2025-152","volume":"17","author":"J Zhu","year":"2025","unstructured":"Zhu J, et al. Development and validation of CT radiomics diagnostic models: differentiating benign from malignant pulmonary nodules and evaluating malignancy degree. J Thorac Disease. 2025;17(3):1645.","journal-title":"J Thorac Disease"},{"issue":"17","key":"7971_CR74","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.3390\/cancers13174271","volume":"13","author":"F Pesapane","year":"2021","unstructured":"Pesapane F, et al. Radiomics of MRI for the prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients: a single referral centre analysis. Cancers. 2021;13(17):4271.","journal-title":"Cancers"},{"issue":"1115","key":"7971_CR75","doi-asserted-by":"publisher","first-page":"20200287","DOI":"10.1259\/bjr.20200287","volume":"93","author":"T Bian","year":"2020","unstructured":"Bian T, et al. Radiomic signatures derived from multiparametric MRI for the pretreatment prediction of response to neoadjuvant chemotherapy in breast cancer. Br J Radiol. 2020;93(1115):20200287.","journal-title":"Br J Radiol"},{"issue":"1","key":"7971_CR76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12645-024-00285-z","volume":"15","author":"S Montazersaheb","year":"2024","unstructured":"Montazersaheb S, et al. Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC). Cancer Nanotechnol. 2024;15(1):47.","journal-title":"Cancer Nanotechnol"},{"issue":"2","key":"7971_CR77","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1574893616666210708143556","volume":"17","author":"Z Ye","year":"2022","unstructured":"Ye Z, et al. Cervical cancer metastasis and recurrence risk prediction based on deep convolutional neural network. Curr Bioinform. 2022;17(2):164\u201373.","journal-title":"Curr Bioinform"},{"issue":"6","key":"7971_CR78","doi-asserted-by":"publisher","first-page":"e190168","DOI":"10.1148\/ryai.2020190168","volume":"2","author":"R Verma","year":"2020","unstructured":"Verma R, et al. Tumor Habitat-derived Radiomic Features at Pretreatment MRI That Are Prognostic for Progression-free Survival in Glioblastoma Are Associated with Key Morphologic Attributes at Histopathologic Examination: A Feasibility Study. Radiol Artif Intell. 2020;2(6):e190168.","journal-title":"Radiol Artif Intell"},{"issue":"4","key":"7971_CR79","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.3390\/curroncol31040165","volume":"31","author":"EI Styliara","year":"2024","unstructured":"Styliara EI, et al. Survival outcome prediction in glioblastoma: insights from MRI radiomics. Curr Oncol. 2024;31(4):2233\u201343.","journal-title":"Curr Oncol"},{"issue":"3","key":"7971_CR80","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1148\/radiol.2016160845","volume":"280","author":"P Kickingereder","year":"2016","unstructured":"Kickingereder P, et al. Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology. 2016;280(3):880\u20139.","journal-title":"Radiology"},{"issue":"5","key":"7971_CR81","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1158\/1078-0432.CCR-17-2236","volume":"24","author":"K Chang","year":"2018","unstructured":"Chang K, et al. Residual convolutional neural network for the determination of IDH status in low-and high-grade gliomas from MR imaging. Clin Cancer Res. 2018;24(5):1073\u201381.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7971_CR82","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s42256-024-00868-w","volume":"6","author":"R Jiang","year":"2024","unstructured":"Jiang R, et al. A transformer-based weakly supervised computational pathology method for clinical-grade diagnosis and molecular marker discovery of gliomas. Nat Mach Intell. 2024;6(8):876\u201391.","journal-title":"Nat Mach Intell"},{"issue":"3","key":"7971_CR83","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00259-018-4180-3","volume":"46","author":"M Lundemann","year":"2019","unstructured":"Lundemann M, et al. Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46(3):603\u201313.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7971_CR84","doi-asserted-by":"crossref","unstructured":"Huseynova L, Pyruvate kinase modulation in, the brain under stress factors: structural, developmental and molecular perspectives. Adv Biology Earth Sci. 2025;10(3).","DOI":"10.62476\/abes.103488"},{"issue":"23","key":"7971_CR85","doi-asserted-by":"publisher","first-page":"9759","DOI":"10.1039\/D1CS01145F","volume":"51","author":"Y Pan","year":"2022","unstructured":"Pan Y, et al. Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection. Chem Soc Rev. 2022;51(23):9759\u2013830.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"7971_CR86","doi-asserted-by":"publisher","first-page":"9494","DOI":"10.1038\/s41598-023-36298-8","volume":"13","author":"P Rauch","year":"2023","unstructured":"Rauch P, et al. Deep learning-assisted radiomics facilitates multimodal prognostication for personalized treatment strategies in low-grade glioma. Sci Rep. 2023;13(1):9494.","journal-title":"Sci Rep"},{"key":"7971_CR87","doi-asserted-by":"publisher","first-page":"822362","DOI":"10.3389\/fneur.2022.822362","volume":"13","author":"S Katzendobler","year":"2022","unstructured":"Katzendobler S, et al. Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas. Front Neurol. 2022;13:822362.","journal-title":"Front Neurol"},{"key":"7971_CR88","doi-asserted-by":"publisher","first-page":"769188","DOI":"10.3389\/fonc.2021.769188","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, et al. Preoperative Magnetic Resonance Imaging Radiomics for Predicting Early Recurrence of Glioblastoma. Front Oncol. 2021;11:769188.","journal-title":"Front Oncol"},{"issue":"5","key":"7971_CR89","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ijrobp.2021.12.153","volume":"112","author":"Y Lao","year":"2022","unstructured":"Lao Y, et al. Voxelwise Prediction of Recurrent High-Grade Glioma via Proximity Estimation-Coupled Multidimensional Support Vector Machine. Int J Radiat Oncol Biol Phys. 2022;112(5):1279\u201387.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"7971_CR90","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.1002\/mp.17382","volume":"51","author":"E Salari","year":"2024","unstructured":"Salari E, et al. Prediction of early recurrence of adult-type diffuse gliomas following radiotherapy using multi-modal magnetic resonance images. Med Phys. 2024;51(11):8638\u201348.","journal-title":"Med Phys"},{"issue":"2","key":"7971_CR91","first-page":"021219","volume":"5","author":"S Rathore","year":"2018","unstructured":"Rathore S, et al. Radiomic signature of infiltration in peritumoral edema predicts subsequent recurrence in glioblastoma: implications for personalized radiotherapy planning. J Med Imaging (Bellingham). 2018;5(2):021219.","journal-title":"J Med Imaging (Bellingham)"},{"key":"7971_CR92","doi-asserted-by":"crossref","unstructured":"Cepeda S, et al. Predicting regions of local recurrence in glioblastomas using voxel-based radiomic features of multiparametric postoperative MRI. Cancers (Basel). 2023;15(6).","DOI":"10.3390\/cancers15061894"},{"key":"7971_CR93","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/j.wneu.2024.01.002","volume":"183","author":"S Luzzi","year":"2024","unstructured":"Luzzi S, Agosti A. Radiomics Multifactorial in Silico Model for Spatial Prediction of Glioblastoma Progression and Recurrence: A Proof-of-Concept. World Neurosurg. 2024;183:e677\u201386.","journal-title":"World Neurosurg"},{"issue":"2","key":"7971_CR94","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11060-017-2729-9","volume":"137","author":"YB Pan","year":"2018","unstructured":"Pan YB, et al. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma. J Neurooncol. 2018;137(2):395\u2013407.","journal-title":"J Neurooncol"},{"issue":"4","key":"7971_CR95","doi-asserted-by":"publisher","first-page":"e14489","DOI":"10.1111\/cns.14489","volume":"30","author":"WW Duan","year":"2024","unstructured":"Duan WW, et al. A TGF-\u03b2 signaling\u2010related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neurosci Ther. 2024;30(4):e14489.","journal-title":"CNS Neurosci Ther"},{"key":"7971_CR96","doi-asserted-by":"publisher","first-page":"810572","DOI":"10.3389\/fimmu.2022.810572","volume":"13","author":"W-J Zeng","year":"2022","unstructured":"Zeng W-J, et al. A novel inflammation-related lncRNAs prognostic signature identifies LINC00346 in promoting proliferation, migration, and immune infiltration of glioma. Front Immunol. 2022;13:810572.","journal-title":"Front Immunol"},{"key":"7971_CR97","doi-asserted-by":"publisher","first-page":"1383255","DOI":"10.3389\/fimmu.2024.1383255","volume":"15","author":"L Huang","year":"2024","unstructured":"Huang L, et al. Autoimmune encephalitis followed by hemophagocytic lymph histiocytosis: a case report. Front Immunol. 2024;15:1383255.","journal-title":"Front Immunol"},{"key":"7971_CR98","doi-asserted-by":"crossref","unstructured":"Guliyeva A, Abbasova M, Gadzhiev A, Blood leukocyte formula in rats exposed to electromagnetic radiation in prenatal development. Adv Biology Earth Sci. 2025;10(3).","DOI":"10.62476\/abes.103511"},{"issue":"9","key":"7971_CR99","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.30.9.907","volume":"30","author":"FH Hochberg","year":"1980","unstructured":"Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30(9):907\u201311.","journal-title":"Neurology"},{"issue":"2","key":"7971_CR100","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1148\/radiol.2019181296","volume":"290","author":"DP Barboriak","year":"2019","unstructured":"Barboriak DP, et al. Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677\/RTOG 0625 Study. Radiology. 2019;290(2):467\u201376.","journal-title":"Radiology"},{"issue":"1","key":"7971_CR101","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/neuonc\/nou129","volume":"17","author":"A Radbruch","year":"2015","unstructured":"Radbruch A, et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol. 2015;17(1):151\u20139.","journal-title":"Neuro Oncol"},{"key":"7971_CR102","doi-asserted-by":"publisher","first-page":"p6828396","DOI":"10.1155\/2018\/6828396","volume":"2018","author":"A Zikou","year":"2018","unstructured":"Zikou A, et al. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2018;2018:p6828396.","journal-title":"Contrast Media Mol Imaging"},{"issue":"11","key":"7971_CR103","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1182\/blood.V86.11.4184.bloodjournal86114184","volume":"86","author":"G Eissner","year":"1995","unstructured":"Eissner G, et al. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood. 1995;86(11):4184\u201393.","journal-title":"Blood"},{"key":"7971_CR104","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.nantod.2022.101465","volume":"44","author":"Y Li","year":"2022","unstructured":"Li Y, et al. A D-peptide ligand of neuropeptide Y receptor Y1 serves as nanocarrier traversing of the blood brain barrier and targets glioma. Nano Today. 2022;44:101465.","journal-title":"Nano Today"},{"issue":"7","key":"7971_CR105","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/fon.13.271","volume":"10","author":"AJ Walker","year":"2014","unstructured":"Walker AJ, et al. Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression? Future Oncol. 2014;10(7):1277\u201397.","journal-title":"Future Oncol"},{"key":"7971_CR106","doi-asserted-by":"crossref","unstructured":"Da Cruz E, et al. A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers (Basel). 2021;13(8).","DOI":"10.3390\/cancers13081795"},{"issue":"10","key":"7971_CR107","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"6","key":"7971_CR108","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00259-019-04604-0","volume":"47","author":"K Wang","year":"2020","unstructured":"Wang K, et al. Individualized discrimination of tumor recurrence from radiation necrosis in glioma patients using an integrated radiomics-based model. Eur J Nucl Med Mol Imaging. 2020;47(6):1400\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7971_CR109","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1038\/s41598-021-82467-y","volume":"11","author":"YW Park","year":"2021","unstructured":"Park YW, et al. Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation. Sci Rep. 2021;11(1):2913.","journal-title":"Sci Rep"},{"issue":"10","key":"7971_CR110","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1109\/JBHI.2024.3406256","volume":"28","author":"MS Sadique","year":"2024","unstructured":"Sadique MS, et al. Brain Tumor Recurrence vs. Radiation Necrosis Classification and Patient Survivability Prediction. IEEE J Biomed Health Inf. 2024;28(10):5685\u201395.","journal-title":"IEEE J Biomed Health Inf"},{"issue":"3","key":"7971_CR111","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/neuonc\/noy133","volume":"21","author":"JY Kim","year":"2019","unstructured":"Kim JY, et al. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Neuro Oncol. 2019;21(3):404\u201314.","journal-title":"Neuro Oncol"},{"issue":"1","key":"7971_CR112","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1038\/s41467-019-11007-0","volume":"10","author":"N Elshafeey","year":"2019","unstructured":"Elshafeey N, et al. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019;10(1):3170.","journal-title":"Nat Commun"},{"issue":"2","key":"7971_CR113","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11060-013-1059-9","volume":"112","author":"AH Shah","year":"2013","unstructured":"Shah AH, et al. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? J Neurooncol. 2013;112(2):141\u201352.","journal-title":"J Neurooncol"},{"issue":"3","key":"7971_CR114","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3171\/2022.12.JNS222173","volume":"139","author":"JS Young","year":"2023","unstructured":"Young JS, et al. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg. 2023;139(3):748\u201359.","journal-title":"J Neurosurg"},{"issue":"1","key":"7971_CR115","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12885-018-4131-1","volume":"18","author":"S Ranjan","year":"2018","unstructured":"Ranjan S, et al. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer. 2018;18(1):239.","journal-title":"BMC Cancer"},{"key":"7971_CR116","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2020.00024","volume":"10","author":"S Daghighi","year":"2020","unstructured":"Daghighi S, et al. Restriction spectrum imaging differentiates true tumor progression from immune-mediated pseudoprogression: case report of a patient with glioblastoma. Front Oncol. 2020;10:24.","journal-title":"Front Oncol"},{"issue":"8","key":"7971_CR117","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1634\/theoncologist.2020-0085","volume":"25","author":"SF Winter","year":"2020","unstructured":"Winter SF, et al. Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. Oncologist. 2020;25(8):e1221\u201332.","journal-title":"Oncologist"},{"issue":"9","key":"7971_CR118","first-page":"1550","volume":"41","author":"N Soni","year":"2020","unstructured":"Soni N, et al. Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature. AJNR Am J Neuroradiol. 2020;41(9):1550\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"key":"7971_CR119","doi-asserted-by":"crossref","unstructured":"Karabacak M, et al. Radiomics-based machine learning with natural gradient boosting for continuous survival prediction in glioblastoma. Cancers (Basel). 2024;16(21).","DOI":"10.3390\/cancers16213614"},{"issue":"7","key":"7971_CR120","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1097\/JS9.0000000000002488","volume":"111","author":"J Liu","year":"2025","unstructured":"Liu J, et al. Deep learning-based radiomics and machine learning for prognostic assessment in IDH-wildtype glioblastoma after maximal safe surgical resection: a multicenter study. Int J Surg. 2025;111(7):4576\u201385.","journal-title":"Int J Surg"},{"issue":"1","key":"7971_CR121","doi-asserted-by":"publisher","first-page":"27551","DOI":"10.1038\/s41598-024-78705-8","volume":"14","author":"M Zhang","year":"2024","unstructured":"Zhang M, et al. The prognostic value and biological significance of MRI CE-T1-based radiomics models in CNS5-identified GBM: a multi-center study. Sci Rep. 2024;14(1):27551.","journal-title":"Sci Rep"},{"issue":"6","key":"7971_CR122","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/WCO.0000000000001109","volume":"35","author":"P Jamshidi","year":"2022","unstructured":"Jamshidi P, Brat DJ. The 2021 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol. 2022;35(6):764\u201371.","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"7971_CR123","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1002\/cam4.1863","volume":"7","author":"ZC Li","year":"2018","unstructured":"Li ZC, et al. Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma. Cancer Med. 2018;7(12):5999\u20136009.","journal-title":"Cancer Med"},{"key":"7971_CR124","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejrad.2019.01.025","volume":"112","author":"L Han","year":"2019","unstructured":"Han L, et al. MRI texture analysis based on 3D tumor measurement reflects the IDH1 mutations in gliomas - A preliminary study. Eur J Radiol. 2019;112:169\u201379.","journal-title":"Eur J Radiol"},{"key":"7971_CR125","doi-asserted-by":"publisher","first-page":"1265672","DOI":"10.3389\/fonc.2023.1265672","volume":"13","author":"Y Liang","year":"2023","unstructured":"Liang Y, et al. The value of multiparametric MRI radiomics in predicting IDH genotype in glioma before surgery. Front Oncol. 2023;13:1265672.","journal-title":"Front Oncol"},{"issue":"9","key":"7971_CR126","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.clon.2024.05.005","volume":"36","author":"Y-R Huang","year":"2024","unstructured":"Huang Y-R, et al. The Relationship Between the Molecular Phenotypes of Brain Gliomas and the Imaging Features and Sensitivity of Radiotherapy and Chemotherapy. Clin Oncol. 2024;36(9):541\u201351.","journal-title":"Clin Oncol"},{"issue":"1","key":"7971_CR127","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12911-020-01163-5","volume":"20","author":"CH Sudre","year":"2020","unstructured":"Sudre CH, et al. Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status. BMC Med Inf Decis Mak. 2020;20(1):149.","journal-title":"BMC Med Inf Decis Mak"},{"issue":"1","key":"7971_CR128","doi-asserted-by":"publisher","first-page":"13412","DOI":"10.1038\/s41598-022-17707-w","volume":"12","author":"DT Do","year":"2022","unstructured":"Do DT, et al. Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach. Sci Rep. 2022;12(1):13412.","journal-title":"Sci Rep"},{"issue":"1","key":"7971_CR129","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.bjc.6605127","volume":"101","author":"J Dunn","year":"2009","unstructured":"Dunn J, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009;101(1):124\u201331.","journal-title":"Br J Cancer"},{"issue":"1","key":"7971_CR130","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-018-4114-2","volume":"18","author":"Y Han","year":"2018","unstructured":"Han Y, et al. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. BMC Cancer. 2018;18(1):215.","journal-title":"BMC Cancer"},{"issue":"6","key":"7971_CR131","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1118\/1.4948668","volume":"43","author":"P Korfiatis","year":"2016","unstructured":"Korfiatis P, et al. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys. 2016;43(6):2835\u201344.","journal-title":"Med Phys"},{"issue":"1","key":"7971_CR132","doi-asserted-by":"publisher","first-page":"27533","DOI":"10.1038\/s41598-025-08608-9","volume":"15","author":"WS Chen","year":"2025","unstructured":"Chen WS, et al. Prediction of MGMT methylation status in glioblastoma patients based on radiomics feature extracted from intratumoral and peritumoral MRI imaging. Sci Rep. 2025;15(1):27533.","journal-title":"Sci Rep"},{"issue":"9","key":"7971_CR133","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1007\/s00330-017-5302-1","volume":"28","author":"ZC Li","year":"2018","unstructured":"Li ZC, et al. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. Eur Radiol. 2018;28(9):3640\u201350.","journal-title":"Eur Radiol"},{"key":"7971_CR134","doi-asserted-by":"publisher","first-page":"1611549","DOI":"10.3389\/pore.2024.1611549","volume":"30","author":"J Dai","year":"2024","unstructured":"Dai J, et al. Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment. Pathol Oncol Res. 2024;30:1611549.","journal-title":"Pathol Oncol Res"},{"key":"7971_CR135","doi-asserted-by":"crossref","unstructured":"Gareev I, et al. Harnessing adrenergic receptor pathways in gliomas: from tumor biology to targeted therapies. Adv Biol Earth Sci. 2025;10(2).","DOI":"10.62476\/abes.102245"},{"issue":"1","key":"7971_CR136","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12935-025-03721-1","volume":"25","author":"S Srivastava","year":"2025","unstructured":"Srivastava S, et al. Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance. Cancer Cell Int. 2025;25(1):89.","journal-title":"Cancer Cell Int"},{"key":"7971_CR137","doi-asserted-by":"crossref","unstructured":"Walczak P, et al. Better understanding complex pathomechanisms in central nervous system disorders as a prerequisite for improved diagnostic and therapeutic approaches. Chinese Medical Journals Publishing House Co., Ltd 42 Dongsi Xidajie. 2025;pp. 203\u2013205.","DOI":"10.1002\/nep3.70017"},{"issue":"3","key":"7971_CR138","doi-asserted-by":"publisher","first-page":"341","DOI":"10.14744\/ejmo.2024.54846","volume":"8","author":"M Jema\u00e0","year":"2024","unstructured":"Jema\u00e0 M, Kifagi C. Mps1 knockdown in glioblastoma induces DNA damage and up regulation of histone methyltransferase SETD2. Eurasian J Med Oncol. 2024;8(3):341.","journal-title":"Eurasian J Med Oncol"},{"key":"7971_CR139","doi-asserted-by":"publisher","first-page":"117225","DOI":"10.1016\/j.biopha.2024.117225","volume":"178","author":"F Li","year":"2024","unstructured":"Li F, et al. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1). Biomed Pharmacother. 2024;178:117225.","journal-title":"Biomed Pharmacother"},{"key":"7971_CR140","doi-asserted-by":"publisher","first-page":"34","DOI":"10.25259\/Cytojournal_92_2024","volume":"22","author":"R Ren","year":"2025","unstructured":"Ren R, Li Z, Fang Q. A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1. CytoJournal. 2025;22:34.","journal-title":"CytoJournal"},{"issue":"4","key":"7971_CR141","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41401-021-00679-4","volume":"43","author":"D Ji","year":"2022","unstructured":"Ji D, et al. Role of TRPM2 in brain tumours and potential as a drug target. Acta Pharmacol Sin. 2022;43(4):759\u201370.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"7971_CR142","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3892\/mmr.2020.11160","volume":"22","author":"X Chen","year":"2020","unstructured":"Chen X, et al. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis. Mol Med Rep. 2020;22(2):859\u201369.","journal-title":"Mol Med Rep"},{"issue":"4","key":"7971_CR143","doi-asserted-by":"publisher","first-page":"402","DOI":"10.14744\/ejmo.2024.79543","volume":"8","author":"RA Aman","year":"2024","unstructured":"Aman RA, et al. Advancements in Molecular Biomarkers as Prognostic Predictors for Patients with Glioblastoma: A Systematic Review. Eurasian J Med Oncol. 2024;8(4):402\u20139.","journal-title":"Eurasian J Med Oncol"},{"key":"7971_CR144","doi-asserted-by":"crossref","unstructured":"Li J, et al. Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study. Radiother Oncol. 2025:p. 110993.","DOI":"10.1016\/j.radonc.2025.110993"},{"issue":"23","key":"7971_CR145","doi-asserted-by":"publisher","first-page":"e2402516","DOI":"10.1002\/advs.202402516","volume":"11","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, et al. Carrier-Free Self-Assembly Nano-Sonosensitizers for Sonodynamic-Amplified Cuproptosis-Ferroptosis in Glioblastoma Therapy. Adv Sci (Weinh). 2024;11(23):e2402516.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"7971_CR146","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1111\/jcmm.14976","volume":"24","author":"YB Pan","year":"2020","unstructured":"Pan YB, et al. Transcriptome analyses reveal molecular mechanisms underlying phenotypic differences among transcriptional subtypes of glioblastoma. J Cell Mol Med. 2020;24(7):3901\u201316.","journal-title":"J Cell Mol Med"},{"key":"7971_CR147","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3389\/fonc.2020.01057","volume":"10","author":"YB Pan","year":"2020","unstructured":"Pan YB, et al. Prognostic and Predictive Value of a Long Non-coding RNA Signature in Glioma: A lncRNA Expression Analysis. Front Oncol. 2020;10:1057.","journal-title":"Front Oncol"},{"issue":"8","key":"7971_CR148","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750\u201368.","journal-title":"Ann Oncol"},{"key":"7971_CR149","doi-asserted-by":"publisher","first-page":"101375","DOI":"10.1016\/j.pmatsci.2024.101375","volume":"148","author":"J Cheng","year":"2025","unstructured":"Cheng J, et al. Bioengineering nanomaterials for tumor therapy and anti-metastasis. Prog Mater Sci. 2025;148:101375.","journal-title":"Prog Mater Sci"},{"key":"7971_CR150","doi-asserted-by":"crossref","unstructured":"Lei Y, et al. Parallel resonant magnetic field generator for biomedical applications. IEEE Trans Biomed Circuits Syst. 2024.","DOI":"10.1109\/TBCAS.2024.3450881"},{"key":"7971_CR151","doi-asserted-by":"crossref","unstructured":"Qian K, et al. Potential of ultrashort pulsed electric fields to disrupt dense structure in glioma tumors. IEEE Trans Biomed Eng. 2025.","DOI":"10.1109\/TBME.2025.3565520"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07971-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:02:57Z","timestamp":1776337377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07971-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7971"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07971-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript is a review of previously published literature and does not involve new studies with human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not include any individual person\u2019s data in any form (including images or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"516"}}